To Determine Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors

Neoplasms Clinical Trial

Official title:

An Open Label Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01028755
• Other study ID #: 12671
• Status: Completed
• Phase: Phase 1
• First received: November 4, 2009
• Last updated: January 19, 2015
• Start date: November 2009
• Est. completion date: April 2013

Study information

• Verified date: January 2015
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is the first time this drug will be tested in humans in order to determine the safety of the drug, the ability to tolerate the drug, to measure how the drug is used in the body and as a result of these tests to determine a maximum dose to be given. Specifically, the following aspects will be investigated:

• side effects of BAY79-4620 given as infusion every three weeks

• evaluation of highest and safest dose of BAY79-4620

• distribution and concentration of BAY79-4620 in the blood at specific times after administration

• effect of BAY79-4620 on tumor growth

• assessment of "biomarkers" (eg, analysis of specific proteins in blood samples, or analysis of tumor tissue sampled at the time of cancer diagnosis) for changes during the treatment or prediction of safety or benefits of the treatment with BAY79-4620.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: April 2013
• Est. primary completion date: April 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age greater than/equal to 18 years old.

• ECOG Performance Status of 0 - 2

• Life expectancy of at least 12 weeks

• Patients with advanced, histologically or cytological confirmed solid tumors, refractory to any standard therapy or have no standard therapy available

• Radiographically or clinically evaluable tumor

• Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 14 days prior to start of first dose:

• Hemoglobin > 10.0 g/dL

• Absolute neutrophil count (ANC) > or = 1500/mm3

• Platelet count > or = 100,000 /mm3

• Total bilirubin < or = 1.5 times the upper limit of normal

• ALT and AST < or = 2.5 x upper limit of normal (< or = 5 x upper limit of normal for patients with liver involvement)

• INR less than or = 1.5 and a PTT within normal limits (patients who do not undergo an anticoagulative treatment, but have an abnormal high PTT while INR is normal, indicating towards an artificial PTT elevation caused by heparinized, are eligible.

• Serum creatinine < 1.5 times the upper limit of normal

Exclusion Criteria:

• History of impaired cardiac function or clinically significant cardiac disease (i.e. congestive heart failure (CHF) NYHA Class III or IV); myocardial infarction, unstable angina or cardiac arrhythmias requiring anti-arrhythmic therapy < 6 months prior to study entry (beta blockers or digoxin are permitted) and LVEF <40% (as measured at screening by MUGA or echocardiogram).

• Patients with amylase or lipase greater than upper limit of normal range per local laboratory

• History of pancreatitis

• Uncontrolled hypertension defined as systolic blood pressure > 150 mm Hg and/or diastolic blood pressure > 90 mmHg, despite optimal medical management

• Symptomatic metastatic brain or meningeal tumors unless the patient is > 6 months from definitive therapy, has no evidence of tumor growth on an imaging study within 2 weeks prior to study entry, and is clinically stable with respect to the tumor at the time of study entry.

• Patients with severe renal impairment or on dialysis

• Known human immunodeficiency virus (HIV) infection or patients with an active hepatitis B or C infection necessitating treatment. Patients with chronic hepatitis B or C are eligible

• Active clinically serious infections > CTCAE Grade 2

• Serious, non-healing wound, ulcer, or bone fracture

• Known or suspected allergy or intolerance to any agent given in the course of this trial

• Previous cancer that is distinct in primary site or histology from actual disease EXCEPT cervical cancer in-situ, treated basal cell carcinoma, superficial bladder tumors [Ta and Tis] or any cancer curatively treated > 3 years prior to study entry

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Neoplasms

Intervention

Drug:
• BAY79-4620
BAY79-4620 will be administered as 1 hour IV infusion. Dose escalation will be dependent on any dose limiting toxicities

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety, tolerability, maximum tolerated dose		2 years	Yes
Primary	Pharmacokinetics profile of BAY79-4620 and its key metabolites		2 years	No
Secondary	Biomarker evaluation		2 years	No
Secondary	Tumor response		2 years	No
Secondary	Immunogenicity		2 years	No

External Links

•   Click here and search for drug information provided by the FDA.
•   Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.
•   Click here to find results for studies related to Bayer Healthcare products.